Private equity's effect on physician practices is usually discussed in financial terms: revenue growth, EBITDA multiples, physician compensation cuts, retention equity mechanics. The conversation tends to stay in the language of capital. What happens to patients inside PE-owned practices is harder to measure. Clinical quality metrics require longitudinal data, controlled comparisons against non-PE practices, and access to procedure-level records that aren't typically public, and most of the PE-versus-independent comparisons that circulate in industry discussion are qualitative, anecdotal, or derived from physician survey data rather than measured clinical outcomes.

In 2024, a peer-reviewed Health Affairs study changed that. Braun, Lelli, and colleagues examined PE-owned ophthalmology practices against matched independent practices and measured the actual clinical procedure mix before and after PE acquisition. The findings were specific, quantitative, and difficult to explain away through clinical judgment or patient-population variation. The headline number: PE-owned ophthalmology practices decreased retinal detachment surgery volume per physician by 19.6% through the third year post-acquisition relative to matched controls. That's not a modest statistical shift; it's a substantial reduction in one of the most time-sensitive, vision-preserving procedures in ophthalmology, executed specifically at practices that PE acquired, relative to otherwise-comparable practices that remained independent. Understanding what that finding actually means (clinically, economically, and structurally) tells capital allocators something concrete about the kind of asset that patient-capital operators are or aren't building when they acquire and operate ophthalmology practices.

The Study Methodology Matters

The Health Affairs paper by Braun et al. used a matched comparison design. PE-acquired ophthalmology practices were compared against a matched cohort of independent practices with similar baseline characteristics: practice size, subspecialty composition, geographic location, and patient demographics. The matching controlled for factors that might otherwise explain procedure-volume differences, isolating the effect of PE ownership itself. The study tracked procedure volume across specific clinical categories pre-acquisition and post-acquisition for three years, with retinal detachment surgery as one of several procedure categories examined, and the reduction in retinal detachment surgeries per physician at PE-acquired practices relative to the matched independent comparison group represented a statistically significant finding that held across the study's specifications.

Peer-reviewed publication in Health Affairs is the relevant quality filter. Health Affairs is the leading policy journal in American health economics, reviewed by health services researchers, and its findings are routinely cited in federal policy discussions, Congressional testimony, and academic literature. The Braun et al. paper isn't an industry advocacy piece; it's methodologically rigorous academic research.

What Retinal Detachment Surgery Represents Clinically

Retinal detachment is a sight-threatening ophthalmic emergency. When the neurosensory retina separates from the underlying retinal pigment epithelium, the detached portion loses its blood supply and begins dying within hours to days, and without urgent surgical intervention, retinal detachment causes permanent vision loss in the affected area, often progressing to functional blindness in the affected eye. Surgical repair of retinal detachment is performed through vitrectomy, scleral buckle, or pneumatic retinopexy approaches, depending on detachment characteristics. The procedures are technically demanding, require subspecialty retina surgeon training, and must be executed quickly once detachment is diagnosed. Outcomes depend on surgical timing, surgical technique, and follow-up care.

Reimbursement for retinal detachment surgery under Medicare is lower per case than many other vitrectomy procedures. The procedures are time-intensive, use expensive surgical equipment and consumables, and require post-operative monitoring that generates additional physician time without proportional reimbursement. Compared to higher-margin retina procedures like anti-VEGF injection administration (which generate substantial drug pass-through revenue) or certain vitreoretinal surgeries for complex cases (which reimburse at higher rates), retinal detachment surgery has less favorable economics for the practice. The clinical value is vision preservation for patients facing imminent blindness; the economic value to the practice is lower than other retina procedures available to the same patient population and surgeon skill set.

Why the Reduction Matters

A double-digit reduction in retinal detachment surgeries per physician, statistically controlled against matched independent practices, is difficult to explain through clinical judgment variation. Retinal detachment is a relatively binary diagnosis (either the retina is detached or it isn't), and surgical indication is similarly well-defined in the clinical literature. The clinical community has established standards for when retinal detachment surgery is appropriate. If PE-acquired practices were performing fewer of these surgeries because they were appropriately avoiding unnecessary procedures, the data would show improved clinical outcomes at PE practices. The study didn't find that outcome. The procedure-volume drop coincided with patterns consistent with PE practices shifting procedure mix away from lower-margin procedures and toward higher-margin procedures available to the same patient population.

The Braun et al. paper examined this pattern across multiple procedure categories. The retinal detachment reduction was one component of a broader pattern where PE-owned ophthalmology practices adjusted clinical procedure mix in ways consistent with margin optimization at the practice level. Higher-margin procedures (anti-VEGF injections with favorable drug pass-through economics, certain complex vitreoretinal surgeries with higher reimbursement rates) showed increased volume at PE practices, while lower-margin procedures showed reduced volume. The clinical implication is specific: patients presenting with retinal detachment at PE-acquired ophthalmology practices were statistically less likely to receive the indicated surgery than equivalent patients presenting at independent practices, and the difference compounded into a measurable structural shift in how PE-owned practices were managing clinical demand.

This isn't a moral allegation; it's a measured outcome that reflects how practice ownership structure influences procedure mix decisions. When practice ownership is structured around fund-cycle return generation, with sponsor-level pressure on EBITDA growth and margin expansion, the incentive gradient within the practice adjusts in ways that show up in procedure selection data.

The Pattern Across Clinical Metrics

The Braun et al. study wasn't alone in documenting clinical quality changes at PE-owned physician practices. A broader body of peer-reviewed literature has examined PE acquisition effects across specialties, and the pattern is directionally consistent. Physician turnover at PE-acquired ophthalmology practices increased 13 percentage points in absolute terms relative to non-PE practices, representing a 265% relative increase per Singh et al. Health Affairs 2025 research. 70% of physicians exiting PE-acquired ophthalmology practices were under age 60, suggesting voluntary departures rather than retirement transitions, and clinician replacement ratios (new hires per departure) ran 2.28 at PE-acquired practices versus 1.08 at non-PE practices, indicating churn-based rather than growth-based staffing.

Drug switching at PE-acquired retina practices shifted toward higher-cost biologic injections with favorable drug pass-through economics. The cost differential between ranibizumab (Lucentis) at roughly $1,186 per injection and bevacizumab (off-label Avastin) at approximately $90 per injection creates substantial margin opportunity that flows to the practice through drug acquisition and administration, and clinical research has documented prescribing pattern shifts at PE-acquired practices that favor the more expensive drugs over clinically comparable alternatives. Patient satisfaction scores declined 5.2 percentage points by year three at PE-acquired physician practices relative to matched controls across specialties, per peer-reviewed health services research: the decline is modest but statistically significant and directionally consistent with other clinical quality metrics.

A 2025 survey of vitreoretinal fellows documented that 81.4% of respondents flagged autonomy and job-security concerns as primary reasons to avoid PE-owned practices, and separately, 78% of ophthalmology trainees indicated they would not consider employment at a PE-backed practice. The workforce data reflects how the specialty's next generation perceives the clinical environment inside PE-owned practices. The Senate Budget Committee's January 2025 bipartisan report "Profits Over Patients" (led by Senators Whitehouse and Grassley) documented similar patterns across PE-acquired healthcare facilities, including Prospect Medical (Leonard Green) and Lifepoint (Apollo): understaffing, safety violations, and facility closures tied to PE ownership structures optimizing for sponsor returns rather than clinical operations.

What This Tells Capital Allocators

The clinical data matters to capital allocators for a specific reason. The Braun et al. findings and the broader pattern of PE-practice clinical quality research indicate that PE ownership structures systematically adjust clinical procedure mix in ways measurable through peer-reviewed research. For capital that intends to build durable ophthalmology assets over long time horizons, that matters. A practice that systematically reduces vision-preserving surgical volume over three years is a different asset than a practice that maintains its procedure mix on clinical grounds. The first practice has optimized for near-term margin; the second practice has preserved long-term clinical reputation and referral relationships.

In ophthalmology specifically, practice reputation compounds across decades. Referring optometrists, primary care physicians, and other specialists build referral patterns based on clinical reputation, patients select ophthalmologists based on outcomes and community standing, and a practice that builds its reputation over 40 years generates referral and patient flow that can't be replicated through short-term margin optimization. A practice that systematically adjusts procedure mix toward margin and away from indicated clinical work may generate better short-term financials but degrade the referral and reputation base that supports long-term revenue. The capital structure that holds a practice indefinitely has structural incentives aligned with long-term clinical reputation maintenance, while the capital structure that holds a practice for a 5-year exit cycle has structural incentives aligned with near-term margin optimization that translates into higher exit multiples.

The Braun et al. finding is the clinical evidence that those different incentive structures produce measurably different clinical outcomes over time. The procedure-mix shift was small enough to be invisible in any single year but compounds into a meaningfully different practice character over three to five years. For patient-capital operators acquiring ophthalmology practices with indefinite hold intent, the clinical data reinforces what the capital structure already implies: aligning ownership incentives with long-term practice reputation produces durably stronger asset characteristics than aligning ownership incentives with near-term exit multiples. That's not a moral argument but an asset-quality argument. The practice that maintains its clinical procedure mix over 30 years is a better asset than the practice that optimizes its procedure mix over 5 years, because long-term referral and reputation compounds in ways that short-term margin optimization doesn't, and the Health Affairs finding is the measured evidence that the difference between those two types of practices is real, peer-reviewed, and quantifiable.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com